New hope for tough prostate cancer: BNT324 takes on chemo in major trial

NCT ID NCT07365995

Recruiting now Disease control Sponsor: BioNTech SE Source: ClinicalTrials.gov ↗

First seen Jan 30, 2026 · Last updated May 08, 2026 · Updated 10 times

Summary

This study tests if a new drug called BNT324 works better than standard chemotherapy (docetaxel plus steroids) for men with a type of advanced prostate cancer that no longer responds to hormone therapy. About 736 men who have already tried one hormone treatment but not chemotherapy will be randomly assigned to receive either BNT324 or the standard chemo. The main goals are to see if BNT324 helps them live longer and delays cancer growth.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Maryland Oncology Hematology
RECRUITING

Rockville, Maryland, 20850, United States
SCRI Oncology Partners
RECRUITING

Nashville, Tennessee, 37203, United States
Texas Oncology Gulf Coast
RECRUITING

Houston, Texas, 77024, United States
Texas Oncology South Austin
RECRUITING

Austin, Texas, 78731, United States
Texas Oncology, P.A. - Tyler
RECRUITING

Tyler, Texas, 75702, United States

Conditions

Explore the condition pages connected to this study.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER